Lutetium, ac­tini­um or lead: Can iso­tope type of­fer an edge in ra­dio­ther­a­py?

Once con­sid­ered a niche can­cer ther­a­py, ra­di­oli­gands are in the midst of a re­nais­sance.

“If you think about where AD­Cs were four or five years ago, that’s rough­ly where ra­di­oli­gand ther­a­pies [RLT] are now,” No­var­tis’ head of ra­di­oli­gand ther­a­pies Jee­van Virk told End­points News in an in­ter­view. No­var­tis is one of the big names in the space, with the US ap­provals of Lu­tathera and Plu­vic­to in 2018 and 2022, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER